Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Midwest Immunology
1501
mi
from 91732
Plymouth, MN
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Midwest Immunology
1501
mi
from 91732
Plymouth, MN
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Midlands Pediatrics PC
1293
mi
from 91732
Papillion, NE
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Midlands Pediatrics PC
1293
mi
from 91732
Papillion, NE
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Winthrop Allergy and Immunology
2451
mi
from 91732
Mineola, NY
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Winthrop Allergy and Immunology
2451
mi
from 91732
Mineola, NY
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Oklahoma Institute of Allergy & Asthma Clinical Research
1164
mi
from 91732
Oklahoma City, OK
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Oklahoma Institute of Allergy & Asthma Clinical Research
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Allergy and Clinical Immunology Associates
2119
mi
from 91732
Pittsburgh, PA
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Allergy and Clinical Immunology Associates
2119
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Allergy, Asthma & Immunology Clinic, P.A.
1212
mi
from 91732
Irving, TX
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Allergy, Asthma & Immunology Clinic, P.A.
1212
mi
from 91732
Irving, TX
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
IMMUNOe International Research Centers
824
mi
from 91732
Thornton, CO
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
IMMUNOe International Research Centers
824
mi
from 91732
Thornton, CO
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
UCLA CARE Center CRS (601)
13
mi
from 91732
Los Angeles, CA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
UCLA CARE Center CRS (601)
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Colorado Hospital CRS (6101)
825
mi
from 91732
Aurora, CO
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Colorado Hospital CRS (6101)
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Massachusetts General Hospital ACTG CRS (101)
2578
mi
from 91732
Boston, MA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Massachusetts General Hospital ACTG CRS (101)
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
2244
mi
from 91732
Rochester, NY
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
2244
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Unc Aids Crs
2194
mi
from 91732
Chapel Hill, NC
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Unc Aids Crs
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Univ. of Cincinnati CRS (2401)
1880
mi
from 91732
Cincinnati, OH
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Univ. of Cincinnati CRS (2401)
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Case CRS (2501)
2032
mi
from 91732
Cleveland, OH
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Case CRS (2501)
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Vanderbilt Therapeutics CRS (3652)
1763
mi
from 91732
Nashville, TN
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Vanderbilt Therapeutics CRS (3652)
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Houston AIDS Research Team CRS (31473)
1357
mi
from 91732
Houston, TX
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Houston AIDS Research Team CRS (31473)
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Puerto Rico-AIDS CRS (5401)
3356
mi
from 91732
San Juan,
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Puerto Rico-AIDS CRS (5401)
3356
mi
from 91732
San Juan,
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Washington AIDS CRS (1401)
961
mi
from 91732
Seattle, WA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Washington AIDS CRS (1401)
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Washington U CRS (2101)
1573
mi
from 91732
Saint Louis, MO
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Washington U CRS (2101)
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
First Allergy and Clinical Research Center
818
mi
from 91732
Centennial, CO
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
First Allergy and Clinical Research Center
818
mi
from 91732
Centennial, CO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Allergy Associates of the Palm Beaches, PA
2302
mi
from 91732
North Palm Beach, FL
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Allergy Associates of the Palm Beaches, PA
2302
mi
from 91732
North Palm Beach, FL
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Pediatrics Allergy/Immunology Association, PA
1223
mi
from 91732
Dallas, TX
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Pediatrics Allergy/Immunology Association, PA
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
818
mi
from 91732
Centennial, CO
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
818
mi
from 91732
Centennial, CO
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2302
mi
from 91732
North Palm Beach, FL
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2302
mi
from 91732
North Palm Beach, FL
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2202
mi
from 91732
Durham, NC
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2202
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1400
mi
from 91732
Galveston, TX
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1400
mi
from 91732
Galveston, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
UCLA CARE Center CRS (601)
13
mi
from 91732
Los Angeles, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
UCLA CARE Center CRS (601)
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Ucsd, Avrc Crs (701)
105
mi
from 91732
San Diego, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Ucsd, Avrc Crs (701)
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Ucsf Aids Crs (801)
355
mi
from 91732
San Francisco, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Ucsf Aids Crs (801)
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Colorado Hospital CRS (6101)
825
mi
from 91732
Aurora, CO
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Colorado Hospital CRS (6101)
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Northwestern University CRS (2701)
1729
mi
from 91732
Chicago, IL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Northwestern University CRS (2701)
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Rush Univ. Med. Ctr. ACTG CRS (2702)
1729
mi
from 91732
Chicago, IL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Rush Univ. Med. Ctr. ACTG CRS (2702)
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Brigham and Women's Hosp. ACTG CRS (107)
2578
mi
from 91732
Boston, MA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Brigham and Women's Hosp. ACTG CRS (107)
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Massachusetts General Hospital ACTG CRS (101)
2578
mi
from 91732
Boston, MA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Massachusetts General Hospital ACTG CRS (101)
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Unc Aids Crs
2194
mi
from 91732
Chapel Hill, NC
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Unc Aids Crs
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Moses H. Cone Memorial Hospital CRS (3203)
2151
mi
from 91732
Greensboro, NC
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Moses H. Cone Memorial Hospital CRS (3203)
2151
mi
from 91732
Greensboro, NC
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Univ. of Cincinnati CRS (2401)
1880
mi
from 91732
Cincinnati, OH
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Univ. of Cincinnati CRS (2401)
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
The Ohio State Univ. AIDS CRS (2301)
1960
mi
from 91732
Columbus, OH
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
The Ohio State Univ. AIDS CRS (2301)
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Vanderbilt Therapeutics CRS (3652)
1763
mi
from 91732
Nashville, TN
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Vanderbilt Therapeutics CRS (3652)
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Houston AIDS Research Team CRS (31473)
1357
mi
from 91732
Houston, TX
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Houston AIDS Research Team CRS (31473)
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
31788 Alabama CRS
1785
mi
from 91732
Birmingham, AL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
31788 Alabama CRS
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Southern California (1201)
13
mi
from 91732
Los Angeles, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Southern California (1201)
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Colorado Denver ATN CRS (33022)
818
mi
from 91732
Denver, CO
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Colorado Denver ATN CRS (33022)
818
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Georgetown University CRS (GU CRS) (1008)
2281
mi
from 91732
Washington,
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Georgetown University CRS (GU CRS) (1008)
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Children's National Med. Ctr. ATN CRS (33003)
2281
mi
from 91732
Washington,
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Children's National Med. Ctr. ATN CRS (33003)
2281
mi
from 91732
Washington,
Click here to add this to my saved trials